MLH1 and endometrial cancer: For MLH1, the highest risk corresponds to colorectal cancer (46%), followed by endometrial (43%), gastrointestinal (21%), ovarian (10%), and urinary cancer (8%); for MSH2, the highest risk relates to endometrial cancer (57%), followed by colorectal (43%), ovarian (17%), urinary (25%), and gastrointestinal cancer (10%); MSH6 displays risk of endometrial (46%), colorectal (15%), ovarian (13%), urinary (11%), and gastrointestinal cancer (7%) [11].